Table 1.
Patient demographics and baseline disease characteristics of patients who received xaluritamig.
| Low-dose cohorts | High-dose cohorts | ||
|---|---|---|---|
| All cohorts | (1–7a) | (7b–13) | |
| (N = 97) | (n = 45) | (n = 52) | |
| Age, median (range), years | 67 (40, 86) | 67 (40, 86) | 68 (51, 85) |
| Race, n (%) | |||
| White | 59 (61) | 29 (64) | 30 (58) |
| Asian | 32 (33) | 13 (29) | 19 (37) |
| Black/African American | 5 (5) | 3 (7) | 2 (4) |
| Not available | 1 (1) | 0 | 1 (2) |
| ECOG PS, n (%) | |||
| 0 | 45 (46) | 19 (42) | 26 (50) |
| 1 | 52 (54) | 26 (58) | 26 (50) |
| Number of prior lines of therapy, n (%) | |||
| 1–2 | 20 (21) | 10 (22) | 10 (19) |
| 3 | 25 (26) | 13 (29) | 12 (23) |
| 4 | 25 (26) | 11 (24) | 14 (27) |
| ≥5 | 27 (28) | 11 (24) | 16 (31) |
| Median, range | 4 (1, 9) | 3 (1, 7) | 4 (1, 9) |
| Number of prior novel hormonal therapies, n (%) | |||
| 0 | 1 (1) | 1 (2) | 0 |
| 1 | 44 (45) | 20 (44) | 24 (46) |
| 2 | 40 (41) | 17 (38) | 23 (44) |
| 3 | 9 (9) | 6 (13) | 3 (6) |
| 4 | 3 (3) | 1 (2) | 2 (4) |
| Number of prior taxanes, n (%) | |||
| 0 | 15 (15) | 8 (18) | 7 (13) |
| 1 | 34 (35) | 18 (40) | 16 (31) |
| 2 | 42 (43) | 17 (38) | 25 (48) |
| 3 | 6 (6) | 2 (4) | 4 (8) |
| Number of prior PSMA-targeting radioligand therapies, n (%) | |||
| 0 | 93 (96) | 44 (98) | 49 (94) |
| 1 | 4 (4) | 1 (2) | 3 (6) |
| Median (range) duration of follow-up, months | 8.1 (0.5, 29.2) | 10.6 (1.2, 29.2) | 6.7 (0.5, 20.9) |
| Median (range) baseline prognostic factors | |||
| PSA, ng/mL | 113.0 (0.2, 5808.9) | 100.3 (1.7, 2740.0) | 123.8 (0.2, 5808.9) |
| Hgb, g/dL | 11.4 (8.0, 14.6) | 11.1 (8.0, 14.4) | 11.8 (8.0, 14.6) |
| Alkaline phosphatase, U/L | 119.5 (29.0, 1767.0) | 121.0 (38.0, 1767.0) | 118.0 (29.0, 1319.0) |
| LDH, U/L | 220.5 (121.0, 3022.0) | 229.0 (121.0, 824.0) | 219.0 (121.0, 3022.0) |
| Albumin, g/dL | 3.8 (2.5, 4.6) | 3.7 (3.0, 4.6) | 3.9 (2.5, 4.6) |
| Sites of metastatic disease, n (%) | |||
| Bone only | 24 (25) | 13 (29) | 11 (21) |
| Lymph node only | 6 (6) | 3 (7) | 3 (6) |
| Bone and lymph node | 15 (15) | 6 (13) | 9 (17) |
| Visceral metastases and other sites | 51 (53) | 23 (51) | 28 (54) |
| Liver | 19 (37) | 6 (26) | 13 (46) |
| No category | 1 (1) | 0 | 1 (2) |
NOTE: Number of prior lines of therapy does not include androgen deprivation therapy or first-generation androgen receptor deprivation therapy.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; Hgb, hemoglobin; LDH, lactate dehydrogenase.